Status:
COMPLETED
Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Kidney Transplantation
Graft Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Graft nephrectomy is associated with massive allo-sensitization following this event. The occurrence of anti-HLA antibodies is a major barrier to perform a second kidney transplantation. Investigators...
Detailed Description
Background: graft nephrectomy is associated with massive allo-sensitization following this event The occurrence of anti-HLA antibodies is a major barrier to perform a second kidney transplantation. Mo...
Eligibility Criteria
Inclusion
- Adult recipients,
- affiliated to the social security
- requiring a graft nephrectomy, with a project to retransplantation
Exclusion
- combined transplantations, PRA \>20%.
- Patient under protective measures,
- Rituximab used for immunosuppression induction
- Previous transplants not removed,
- Active infectious complications at graft nephrectomy, need for immunosuppressive treatments after graft nephrectomy,
- Participation to another interventional studies using Rituximab, polyclonal antibodies, Eculizumab, or Tocilizumab.
- adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision,
- pregnancy or breastfeeding.
Key Trial Info
Start Date :
October 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 9 2024
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04779957
Start Date
October 1 2021
End Date
August 9 2024
Last Update
December 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Toulouse
Toulouse, France